Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 16/09/16 → 15/04/17 |
Funding
- Norfolk & Norwich University Hospitals NHS Foundation Trust: £26,341.62
Developing a new targeted therapy for hormone-refractory prostate cancer: preclinical validation of everolimus-docetaxel containing nanoparticles.
- Cooper, Colin (Principal Investigator)
- Pshezhetskiy, Dmitry (Co-Investigator)
- Wang, Qi (Researcher)